{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:12:21Z","timestamp":1773828741869,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:00:00Z","timestamp":1504310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00198-017-4214-x","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T23:46:16Z","timestamp":1504309576000},"page":"3277-3280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-2688","authenticated-orcid":false,"given":"M.","family":"Celli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"D\u2019Eufemia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Persiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Turchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Febbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"D\u2019Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Celli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,2]]},"reference":[{"key":"4214_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1086\/497706","volume":"77","author":"M Ai","year":"2005","unstructured":"Ai M, Heeger S, Bartels CF, Schelling DK (2005) Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet 77:741\u2013753","journal-title":"Am J Hum Genet"},{"key":"4214_CR2","first-page":"146","volume":"59","author":"Y Gong","year":"1996","unstructured":"Gong Y, Vikkula M, Boon L (1996) Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet 59:146\u2013151","journal-title":"Am J Hum Genet"},{"key":"4214_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/jmg.25.8.543","volume":"25","author":"H Somer","year":"1988","unstructured":"Somer H, Palotie A, Somer M, Hoikka V, Peltonen L (1988) Osteoporosis-psedudoglioma syndrome: clinical, morphological and biochemical studies. J Med Genet 25:543\u2013549","journal-title":"J Med Genet"},{"key":"4214_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1399-0004.1986.tb00822.x","volume":"29","author":"M Frontali","year":"1986","unstructured":"Frontali M, Dallapiccola B (1986) Osteoporosis-pseudoglioma syndrome and the ocular form of osteogenesis imperfect. Clin Genet 29:262","journal-title":"Clin Genet"},{"key":"4214_CR5","first-page":"419","volume":"5","author":"D Lev","year":"2003","unstructured":"Lev D, Binson I, Foldes AJ, Watemberg N, Lerman-Sagie Y (2003) Decreased-bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome. Isr Med Assoc J 5:419\u2013421","journal-title":"Isr Med Assoc J"},{"key":"4214_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","volume":"107","author":"Y Gong","year":"2001","unstructured":"Gong Y, Slee RB, Fukai N, Warman ML (2001) Osteoporosis-pseudoglioma syndrome collaborative group: LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513\u2013523","journal-title":"Cell"},{"key":"4214_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bone.2008.04.020","volume":"43","author":"EA Streeten","year":"2008","unstructured":"Streeten EA, McBride D, Puffenberger E, Hoffman ME, Pollin TI, Donelly P, Sack P, Morton H (2008) Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone 43:584\u2013590","journal-title":"Bone"},{"key":"4214_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1067\/mpd.2000.107838","volume":"137","author":"M Zacharin","year":"2000","unstructured":"Zacharin M, Cundy T (2000) Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. J Pediatr 137:410\u2013415","journal-title":"J Pediatr"},{"key":"4214_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1586\/17446651.3.3.337","volume":"3","author":"R Levasseur","year":"2008","unstructured":"Levasseur R (2008) Treatment and management of osteoporosis-pseudoglioma syndrome. Expert Rev Endocrinol Metab 3:337\u2013348","journal-title":"Expert Rev Endocrinol Metab"},{"key":"4214_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/TCRM.S35788","volume":"9","author":"D Gatti","year":"2013","unstructured":"Gatti D, Rossini M, Viapiana O, Idolazzi L, Adami S (2013) Clinical development of neridronate: potential for new applications. Ther Clin Risk Manag 9:139\u2013147","journal-title":"Ther Clin Risk Manag"},{"key":"4214_CR11","first-page":"55","volume":"20","author":"S Adami","year":"2002","unstructured":"Adami S, Bevilacqua M, Broggini M, Filipponi P, Ortolani S, Palummeri E, Ulivieri F, Nannipieri F, Braga V (2002) Short-term intravenous therapy with neridronate in Paget\u2019s disease. Clin Exp Rheumatol 20:55\u201358","journal-title":"Clin Exp Rheumatol"},{"key":"4214_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tat\u00f2 L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfect: a randomized controlled study. J Bone Miner Res 20:758\u2013763","journal-title":"J Bone Miner Res"},{"key":"4214_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-016-3729-x","volume":"28","author":"P D\u2019Eufemia","year":"2017","unstructured":"D\u2019Eufemia P, Finocchiaro R, Zambrano A, Lodato V, Celli L, Finocchiaro S, Persiani P, Turchetti A, Celli M (2017) Serum creatine kinase isoenzymes in children with osteogenesis imperfect. Osteoporos Int 28:339\u2013346","journal-title":"Osteoporos Int"},{"key":"4214_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/ejhg.2011.42","volume":"19","author":"CM Laine","year":"2011","unstructured":"Laine CM, Chung BD, Susic M, Prescott T, Semler O, Fiskerstrand D\u2019EP, Castori M, Pekkinem M, Sochett E, Cole WG, Netzer C, Makitie O (2011) Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur J Hum Genet 19:875\u2013881","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"4214_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jbmr.2403","volume":"30","author":"N Alonso","year":"2015","unstructured":"Alonso N, Soares DC, McCloskey EV, Summers GD, Raltston SH, Gregson CL (2015) Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5. J Bone Miner Res 30(4):615\u2013620","journal-title":"J Bone Miner Res"},{"key":"4214_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1749-6632.2009.05312.x","volume":"1192","author":"VK Yadav","year":"2010","unstructured":"Yadav VK, Ducy P (2010) LRP5 and bone formation. A serotonin-dependent pathway. Ann N Y Acad Sci 1192:103\u2013109","journal-title":"Ann N Y Acad Sci"},{"key":"4214_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1086\/383202","volume":"74","author":"C Toomes","year":"2004","unstructured":"Toomes C, Bottomley HM, Jackson RM et al (2004) Mutations in LRP5 of FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet 74:721\u2013730","journal-title":"Am J Hum Genet"},{"key":"4214_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jpeds.2006.06.069","volume":"149","author":"N Iorgi Di","year":"2006","unstructured":"Di Iorgi N, Maghnie M (2006) Motor function improvement after intravenous pamidronate in osteoporosis pseudoglioma syndrome. J Pediatr 149:734","journal-title":"J Pediatr"},{"key":"4214_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1515\/JPEM.2006.19.3.275","volume":"19","author":"F Bayram","year":"2006","unstructured":"Bayram F, Tansiverdi F, Kurtoglu S, Atabek ME, Kula M, Kaynar L, Kelestimur F (2006) Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG). J Pediatr Endocrinol Metab 19:275\u2013279","journal-title":"J Pediatr Endocrinol Metab"},{"key":"4214_CR20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1515\/JPEM.2008.21.8.811","volume":"21","author":"ER Barros","year":"2008","unstructured":"Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M (2008) Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 21:911","journal-title":"J Pediatr Endocrinol Metab"},{"key":"4214_CR21","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1002\/jbmr.530","volume":"26","author":"HP Arantes","year":"2011","unstructured":"Arantes HP, Barros ER, Kunii I, Bilezikian JP, Lazaretti-Castro M (2011) Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma. J Bone Miner Res 26:2823\u20132826","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4214-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4214-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T15:00:58Z","timestamp":1552662058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4214-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,2]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["4214"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4214-x","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,2]]},"assertion":[{"value":"9 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}